Meta‐analysis of randomized controlled trials as a method of estimating rare complications of non‐steroidal anti‐inflammatory drug therapy
- 1 April 1988
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 2 (s1), 9-26
- https://doi.org/10.1111/j.1365-2036.1988.tb00761.x
Abstract
The design of randomized controlled trials to assess the efficacy of pharmacological measures for the prevention of the gastrointestinal side-effects of anti-inflammatory drugs requires an accurate estimate of excess risk under controlled conditions. Photocopies of 952 randomized controlled trial publications were obtained after scanning titles and abstracts of a MEDLINE computer search, 427 were excluded for obvious reasons, and 525 were again photocopied after obliterating source and results. Selection criteria were: the presence of a non-anti-inflammatory drug control group; at least 4 days of therapy; at least 3 days without anti-inflammatory drugs before randomization; no complicating background drugs; mention of side-effects; and a clear differentiation of gastrointestinal complications. Observer error, with two independent readings, for inclusion suitability in the study was 19% for Methods and 9% for Results. For the 44 aspirin trials, the mean therapy duration was 357 days; the unweighted rate difference between therapy and control groups ( +/- 1 S.E.M.) for ulcer was 0.006 +/- 0.003, for gross haemorrhage 0.006 +/- 0.002 and for unspecified gastric symptoms 0.03 +/- 0.01. In 123 non-aspirin non-steroidal anti-inflammatory drug (NA-NSAID) trials, the mean duration was 67 days; the unweighted rate difference for ulcer was 0.0005 +/- 0.0003, for gross haemorrhage 0.007 +/- 0.004 and for unspecified gastric symptoms 0.02 +/- 0.005. Risk differences were also pooled using the DerSimonian and Laird method, which weights studies inversely according to variance. Using this method, only the unspecified gastric symptoms for non-aspirin non-steroidal anti-inflammatory drugs (NA-NSAIDs) and the haemorrhage for aspirin were found to be statistically significant. Longer studies have higher risk differences. Randomized control trials to determine prophylactic efficacy against haemorrhage (that is, to demonstrate a reduction of ulcer rate in the therapy group to the rate of controls) would require 190 patients in each group for NA-NSAIDs in studies of 2-6 months; 950 subjects would be needed to detect a 50% reduction. Randomized control trials to determine a reduction in ulcer rate to that of controls in patients on aspirin for more than 6 months would require 700 subjects in each group; 3346 subjects would be needed to detect a 50% reduction. Such studies are feasible.Keywords
This publication has 6 references indexed in Scilit:
- Meta-Analyses of Randomized Controlled TrialsNew England Journal of Medicine, 1987
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Adrenocorticosteroid administration and peptic ulcer: A critical analysisJournal of Chronic Diseases, 1985
- Association of Adrenocorticosteroid Therapy and Peptic-Ulcer DiseaseNew England Journal of Medicine, 1983
- Nonassociation of Adrenocorticosteroid Therapy and Peptic UlcerNew England Journal of Medicine, 1976
- The Combination of Estimates from Different ExperimentsBiometrics, 1954